Radiation and concomitant chemotherapy for patients with glioblastoma multiforme

Chinese Journal of Cancer

Volumn 33, Issue 1, 2014, Pages 25-31

  Villà, Salvador ^a   Balaňà, Carme ^a   Comas, Sílvia ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

Chemotherapy; Concomitant treatment; Glioblastoma multiforme; Radiotherapy

Indexed keywords

BEVACIZUMAB; CARMUSTINE; CORTICOSTEROID; FLUORODEOXYGLUCOSE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METRONIDAZOLE; MISONIDAZOLE; PROCARBAZINE; RADIOSENSITIZING AGENT; TEMOZOLOMIDE;

ACCELERATED FRACTIONATED RADIOTHERAPY; COGNITIVE DEFECT; EXTERNAL BEAM RADIOTHERAPY; GLIOBLASTOMA; HUMAN; HYPERFRACTIONATED RADIOTHERAPY; HYPOFRACTIONATION RADIOTHERAPY; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; QUALITY OF LIFE; RADIATION DOSE; RADIATION NECROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMNOLENCE; STEREOTACTIC BODY RADIATION THERAPY; STEREOTACTIC RADIOSURGERY; SURVIVAL; TOXICITY;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DOSE FRACTIONATION; GLIOBLASTOMA; HUMANS; RADIOSURGERY; TUMOR SUPPRESSOR PROTEINS;

EID: 84891723257     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.013.10216     Document Type: Review

References (36)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med, 2005,352:987-996.
2. Stupp R, Hegi M, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 2009,10:459-466.
3. Chinot O, Wick W, Mason W, et al. Phase III trial of bevacizunab added to standard radiotherapy and temoziolomide for newly diagnosed glioblastoma: final progression-free survival and interim overall survival results in AVAGLIO. Neuro Oncol, 2012,14 suppl 6:vi101-vi105.
4. Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temo-zolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol, 2006,24:2563-2569.
5. Laperriere N, Zuraw L, Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systemic review. Radiother Oncol, 2002,64:259-273.
6. Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain. Neuro Oncol, 2013,15:797-805.
7. Villà S, Viñolas N, Veger E, et al. Efficacy of radiotherapy for malignant gliomas in elderly patients. Int J Radiat Oncol Biol Phys, 1998,42:977-980.
8. Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Eng J Med, 2007,356:1527-1535.
9. Wallner KE, Galicich JH, Krol G, et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys, 1989,16:1405-1409.
10. Baumert BG, Brada M, Bernier J, et al. EORTC 22972-26991/MRC BR10 trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost arm. Radiother Oncol, 2008,88:163-172.
11. Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer, 1991,64:769-774.
12. Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gilomas re evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr, 1988,6:279-284.
13. Scott CB, Curran WJ, Yung WKA, et al. Long-term results of RTOG 9006: a randomized study of hyperfractionated radiotherapy (RT) to 72.0 Gy & carmustine vs. standard RT & carmustine for malignant glioma patients with emphasis on anaplastic astrocytoma patients [abstract]. Proc Ann Meet Am Soc Clin Oncol, 1998,17:401a.
14. Nelson DF, Curran WJ, Scott C, et al. Hyperfractionated radiation therapy and bis-chlorethyl nitrosurea in the treatment of malignant glioma-possible advantage observed at 72.0 Gy in 1.2 Gy BID fractions: report of the Radiation Therapy Oncology Group protocol 8302. Int J Radiat Oncol Biol Phys, 1993,25:193-207.
15. Horiot JC, van den Bogaert W, Ang KK, et al. European Organization for Research and Tretament of Cancer Trials using radiotherapy with multiple fractions per day. Front Radiat Ther Oncol, 1998,18:1935-1939.
16. Brada M, Sharpe G, Rajan B, et al. Modifying radical radiotherapy in high grade gliomas; shortening the treatment time through acceleration. Int J Radiat Oncol Biol Phys, 1999,43:287-292.
17. Prados MD, Wara WM, Sneed PK, et al. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 2001,49:71-77.
18. 2, respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients. Int J Radiat Oncol Biol Phys, 2000,48:1351-1358.
19. Glinski B. Postoperative hypofractionated radiotherapy versus conventionally fractionated radiotherapy in malignant gliomas. A preliminary report on a randomized trial. J Neurooncol, 1993,16:167-172.
20. Floyd NS, Woo SY, Teh BS, et al. Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 2004,58:721-726.
21. Sultanem K, Patrocinio H, Lambert C, et al. The use of hypo-fractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial. Int J Radiat Oncol Biol Phys, 2004,58:247-252.
22. Roa W, Brasher PMA, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol, 2004,22:1583-1588.
23. Urtasun R, Band P, Chapman JD, et al. Radiation and high-dose metronidazole in supratentorial glioblastomas. N Engl J Med, 1976,294:1364-1367.
24. Souhami L, Seiferhield W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. In J Radiat Oncol Biol Phys, 2004,60:853-860.
25. Tsao MN, Mehta MP, Whelan TJ, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Boil Phys, 2005,63:47-55.
26. Binello E, Green S, Germano IM. Radiosurgery for high-grade glioma. Surg Neurol Int, 2012,3 (suppl 2):S118-S126.
27. Soussain C, Ricard D, Fike JR, et al. CNS complications of radiotherapy and chemotherapy. Lancet, 2009,374:1639-1651.
28. Dhermain FG, Hau P, Lanfermann H, et al. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol, 2010,9:906-920.
29. Prokic V, Wiedenmann N, Fel F, et al. Whole brain irradiation with hipoccampal sparing and dose escalation on multiple brain metastases: a planning study on treatment concepts. Int J Radiat Oncol Biol Phys, 2013,85:264-270.
30. Spiegel BM, Esrailian E, Laine L, et al. Clinical impact of adjuvant chemotherapy in glioblastoma multiforme: a meta-analysis. CNS Drugs, 2007,21:775-787.
31. Stewart LA. Chemotherapy in adult high-grade glioma: a systemic review and meta-analysis of individual patient data from 12 ramdomised trials. Lancet, 2002,359:1011-1018.
32. Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008;113:405-410.
33. Brandes AA, Tosoni A, Franceschi E, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol, 2009,27:1275-1279.
34. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elederly: the NOA-08 randomised, phase 3 trial. Lancet Oncol, 2012,13:707-725.
35. Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in pateints older than 60 years with glioblastoma: the Nordic ramdomised, phase 3 trial. Lancet Oncol, 2012,13:916-926.
36. Gilbert M, Dignam J, Won M, et al. RTOG 0825: phase III double-blind placebo-controlled trial evalutaing bevacizumab (Bev) in patients with newly diagnosed glioblastoma. ASCO 2013. J Clin Oncol, 2013,31 (suppl):abst 1.